Biopharma · FDA Approvals · Stock

CTRM Castor Maritime

Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under three reportable segments, namely (i) the dry bulk segment, (ii) the containership segmen…

Assets on file: infliximab-dyyb, omalizumab-igec

Start live analysis of CTRM Run 8-agent AI analysis All sector events →

Catalyst calendar

Dated catalysts for CTRM, including recently decided ones.

October 2026

Oct 2026

~ Oct 2026

CTRMCastor Maritime Inc.

Celltrion to Present ZYMFENTRA Analyses at ACG 2026

Conference presentationCompany press releaseMonth only

Recent first-hand events

Every first-hand event for CTRM, newest first.

Instant stream — events appear as soon as they are filed.

Decision-gradeMaterialNotableMinor

Oct 12, 2026

01:00 AM

CTRMCastor Maritime Inc.

Celltrion to Present ZYMFENTRA Analyses at ACG 2026

Celltrion will present new post-hoc and late-breaking analyses of ZYMFENTRA (infliximab-dyyb) at the ACG 2026 meeting on Oct 13-14. The data compare SC vs IV infliximab in ileum-dominant Crohn's disease and evaluate outcomes after IV-to-SC switch regardless of prior ADA status in CD and UC.

Conference presentationCompany press release

Oct 5, 2026

08:45 PM

CTRMCastor Maritime Inc.

Celltrion launches FDA-approved interchangeable biosimilar OMLYCLO (omalizumab-igec) to XOLAIR

Celltrion announced U.S. commercial availability of OMLYCLO, the first FDA-approved interchangeable biosimilar to XOLAIR approved for all four indications. It is now available in three prefilled syringe strengths for subcutaneous injection. This expands treatment options and access for patients with allergic and inflammatory conditions.

FDA label updateCompany press release Open record